Viewing 21-40 of 71 articles
ASCO 2018: The PROPHECY Trial: Multicenter Prospective Trial of Circulating Tumor Cell AR-V7 Detection in Men with mCRPC Receiving Abiraterone or Enzalutamide
ASCO 2018: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Randomized Phase II Trial
ASCO 2018: Overall Survival Between African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer
ASCO 2018: Results for 2nd-line Therapy: A Cross-over Trial, Abiraterone + Prednisone vs Enzalutamide for Patients Metastatic Castration-Resistant Prostate Cancer
ASCO 2018: Active Surveillance in the Real World: What Have ProtecT and Other Prospective Trials Taught Us?
ASCO 2018: A Prospective Phase 2/3 Multicenter Study of 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer: Examination of Diagnostic Accuracy (OSPREY)
ASCO 2018: A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with Metastatic Castrate Sensitive Prostate Cancer (mCSPC)
ASCO 2018: The Association of BRCA1 and BRCA2 Mutations on Prostate Cancer Risk, Frequency, and Mortality: Systematic Review and Meta-Analysis
ASCO 2018: The GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer in Washington State and Beyond
ASCO 2018: Subsequent Treatment after Abiraterone Acetate + Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-naïve Prostate Cancer: LATITUDE
ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort
ASCO 2018: Sipuleucel-T OS and Clinical Outcomes by Baseline PSA Quartiles in Patients with mCRPC: PROCEED Registry
ASCO 2018: Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy?
ASCO 2018: Abiraterone Acetate and Prednisone, AAP Plus Degarelix, and Degarelix Alone for Patients with Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy
ASCO 2018: KEYNOTE-046: ADXS-PSA Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer